Heart failure & cardiomyopathies
Treatment Patterns of Patients with Worsening Heart Failure with Reduced Ejection Fraction
Authors' conclusion
Major gaps in use of GDMT, particularly combination therapy, remain among US HFrEF patients. These gaps persist during longitudinal follow-up and are particularly large among patients with recent WHFE.
Study context
- Population
- Outpatients with HF and EF < 45%, US, 2017–2019458 panel + 1000 Geisinger Health System (GHS) patients
- Exposure
- HFrEF patients with vs without worsening HF events (WHFE)
- Outcome
- Treatment patterns: proportion receiving ≥50% of guideline-recommended dose of GDMT on index visit
- Follow-up
- Index visit
Methodological detailsnationwide panel of 238 cardiologists and Geisinger Health System records, Retrospective electronic medical records
- Nationwide panel of 238 cardiologists and Geisinger Health System records
- Retrospective electronic medical records
Main finding
As reported in the abstract
Receiving ≥50% of guideline-recommended dose on index visit, nationwide panel
Beta blocker
ACEI/ARB/ARNI
MRA
Observational data: associations, not effects.
Further findings
Patients receiving ≥50% of guideline-recommended dose at index visit, GHS (with vs without WHFE)
- Beta-blocker, with vs without WHFE
- 29% versus 34%
- ACEI/ARB/ARNI, with vs without WHFE
- 16% versus 31%
- MRA, with vs without WHFE
- 18% versus 22%
- Lower in GHS than nationwide panel
Triple therapy on index date (with vs without WHFE)
- Nationwide panel, with vs without WHFE
- 42% and 44%
- GHS, with vs without WHFE
- 14% and 17%
Patients on no GDMT, GHS: end of index visit vs 12-month follow-up
- WHFE cohort, index visit to 12 months
- 14% to 28%
- Non-WHFE, index visit to 12 months
- 14 to 21%
Original publication
Treatment Patterns of Patients with Worsening Heart Failure with Reduced Ejection Fraction. ESC Heart Fail. Published 19 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →